NICE does not recommend risdiplam for treating spinal muscular atrophy

NICE has published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA). SMA is a progressive neuromuscular condition affecting the nerves in the spinal cord controlling movement. This leads to muscle weakness, progressive loss of movement, and difficulty breathing and swallowing.
Source: NHS Networks - Category: UK Health Source Type: news